{\rtf1 \ansi 
{\colortbl;
\red0\green0\blue0;
\red255\green255\blue255;
\red255\green0\blue0;
\red0\green255\blue0;
\red0\green0\blue255;
\red0\green255\blue255;
\red255\green0\blue255;
\red255\green255\blue0;
\red0\green0\blue128;
\red0\green128\blue128;
\red0\green128\blue0;
\red128\green0\blue128;
\red128\green0\blue0;
\red128\green128\blue0;
\red128\green128\blue128;
\red192\green192\blue192;
\red170\green170\blue170;
\red85\green85\blue85;
\red14\green86\blue140;
\red37\green37\blue37;
\red33\green33\blue33;
\red119\green119\blue119;
\red107\green107\blue106;
\red255\green255\blue102;
\red190\green190\blue252;
\red80\green80\blue80;
\red51\green51\blue51;
\red254\green254\blue0;
\red56\green124\blue43;
\red204\green204\blue204;
\red151\green151\blue151;
\red246\green246\blue246;
\red21\green137\blue21;
\red247\green247\blue247;
\red238\green238\blue238;
\red20\green93\blue164;
\red181\green79\blue104;
\red233\green233\blue233;
\red112\green112\blue112;
\red0\green114\blue54;
\red240\green240\blue240;
\red105\green105\blue105;
\red106\green144\blue39;
\red187\green187\blue187;
\red255\green255\blue174;
\red255\green248\blue96;
\red232\green233\blue232;
\red249\green249\blue249;
\red118\green118\blue118;
\red239\green122\blue2;
\red255\green194\blue211;
\red203\green203\blue203;
\red245\green245\blue245;
\red229\green243\blue255;
\red179\green218\blue255;
\red204\green255\blue255;
\red61\green61\blue61;
\red188\green41\blue30;
\red190\green237\blue228;
\red236\green236\blue236;
\red127\green127\blue127;
\red149\green246\blue220;
\red227\green227\blue227;
\red71\green120\blue194;
\red102\green0\blue102;
}
{\fonttbl {
\f0 Arial;}{
\f1 Symbol;}{
\f2 Times New Roman;}{
\f3 georgia;}{
\f4 sans-serif;}{
\f5 Source Sans Pro;}{
\f6 serif;}{
\f7 Courier New;}
}
{\*\generator Apache XML Graphics RTF Library;}
\fet0 \ftnbj 
{\*\listtable
{\list\listtemplateid1656989446\listsimple{\listlevel\leveljc\levelfollow0\levelspace0\levelindent0{\leveltext\'01\u160\'3f}{\levelnumbers}}{\listname ;}\listid246318418}
}
{\*\listoverridetable
{\*\listoverride{\listid246318418\listoverridecount0\ls1}}
}
\paperw12240 \paperh15840 \margt1080 \margb1080 \margl1080 \margr1080 \headery720 \footery720 \itap0 \cols2 
\sectd {\header {
{\trowd \ltrrow \trleft0 
\clpadb60 \clpadfb3 \clpadl400 \clpadfl3 \clbrdrt \clbrdrb \brdrcf17 \brdrw20 \brdrs \clbrdrl \trql \clvertalb \clwWidth9380 \cellx9380 
\clpadb60 \clpadfb3 \clpadl400 \clpadfl3 \clbrdrt \clbrdrb \brdrcf17 \brdrw20 \brdrs \clbrdrr \trql \clwWidth700 \cellx10080 
\intbl 
{\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 
{\b0 \cf1 \f0 \ul0 \strike0 \i0 \fs18 
}
{\b1 \cf18 \f0 \i0 \fs18 
{\b1 \cf18 \f0 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Roche Molecular Systems, Inc. v. CEPHEID, 905 F.3d 1363 (2018)
}
}
{\b0 \cf1 \f0 \ul0 \strike0 \i0 \fs18 
}
}\b0 \cf1 \f0 \ri0 \ul0 \strike0 \i0 \ql \fs18 \li0 \sa0 \sb0 \intbl \cell \intbl 
{\qr \b0 \cf1 \f0 \ri0 \i0 \fs18 \li0 
}\qr \b0 \cf1 \f0 \ri0 \i0 \fs18 \li0 \intbl \cell \row }
{\trowd \lastrow \trleft0 
\clbrdrb \clbrdrl \trql \clwWidth10080 \cellx10080 
\intbl 
{\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 
{\b0 \cf1 \f0 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
128 U.S.P.Q.2d 1221
}
}\b0 \cf1 \f0 \ri0 \ul0 \strike0 \i0 \ql \fs18 \li0 \sa0 \sb0 \intbl \cell \row }}\par }{\footer {
{\trowd \lastrow \trleft0 
\clpadl60 \clpadfl3 \clbrdrt \brdrcf17 \brdrw20 \brdrs \clbrdrb \clbrdrl \trql \clvertalb \clwWidth9300 \cellx9300 
\clpadl60 \clpadfl3 \clbrdrt \brdrcf17 \brdrw20 \brdrs \clbrdrb \clbrdrr \trql \clwWidth700 \cellx10000 
\intbl 
{\b0 \cf17 \f0 \ri0 \i0 \ql \fs20 \li0 
{\b0 \cf17 \f0 \ul0 \strike0 \i0 \fs20 
}
{\*\shppict {\pict \pngblip \picw78 \pich10 \picwgoal1170 \pichgoal150 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}}
{\b0 \cf17 \f0 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u169\'3f 2021 Thomson Reuters. No claim to original U.S. Government Works.
}
}\b0 \cf17 \f0 \ri0 \ul0 \strike0 \i0 \ql \fs20 \li0 \sa0 \sb0 \intbl \cell \intbl 
{\qr \b0 \cf17 \f0 \ri0 \i0 \fs20 \li0 
{\b0 \i0 \ul0 \fs20 \f0 \chpgn }
}\qr \b0 \cf17 \f0 \ri0 \ul0 \strike0 \i0 \fs20 \li0 \intbl \cell \row }}\par }
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_document_4}{\*\bkmkend co_document_4}
{\b0 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart Ie8967be0cbdc11e88037ff68a1223ab1_Target}{\*\bkmkend Ie8967be0cbdc11e88037ff68a1223ab1_Target}
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 
{\*\bkmkstart co_readingModeKC_4}{\*\bkmkend co_readingModeKC_4}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 
{\*\bkmkstart co_readingModeCitatorFlag_4}{\*\bkmkend co_readingModeCitatorFlag_4}
{\b0 \cf1 \f2 \i0 \fs16 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/RelatedInformation/Flag?documentGuid=Ie8967be0cbdc11e88037ff68a1223ab1&transitionType=Document&originationContext=docHeaderFlag&Rank=0&rs=cblt1.0&vr=3.0&contextData=(sc.Search)" }{\fldrslt 
{\*\shppict {\pict \pngblip \picw16 \pich16 \picwgoal255 \pichgoal255 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}}}}
{\b0 \cf1 \f2 \i0 \fs16 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
KeyCite Yellow Flag - Negative Treatment
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 
{\*\bkmkstart co_readingModeNegativeTreatment_4}{\*\bkmkend co_readingModeNegativeTreatment_4}
{\b0 \cf1 \f2 \i0 \fs16 {\fi-360 \li {\*\pn \pnlvlblt \ilvl0 \ls1 \pnindent0 \pnf1 {\f2 \pntxtb \u160\'3f}}{\listtext \b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 \u160\'3f\tab }\ls1 {\pntext }
{\pard }\b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 
{\b0 \cf1 \f2 \i0 \fs16 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
Distinguished by 
}
}
{\field {\*\fldinst HYPERLINK "https://www.westlaw.com/Document/I2cc4e540346311eb9b44df4904fdd6f7/View/FullText.html?navigationPath=RelatedInfo%2Fv4%2Fkeycite%2Fnav%2F%3Fguid%3DI2cc4e540346311eb9b44df4904fdd6f7%26ss%3D2045678900%26ds%3D2052478920%26origDocGuid%3DIe8967be0cbdc11e88037ff68a1223ab1&listSource=RelatedInfo&list=NegativeCitingReferences&rank=0&ppcid=20e873d6dc7a49b0b57732f8e6fa0421&originationContext=docHeader&transitionType=NegativeTreatment&contextData=%28sc.Search%29&VR=3.0&RS=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
Abbott Laboratories v. Grifols Diagnostic Solutions Inc.
}
{\b0 \cf19 \f2 \i0 \fs16 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
, 
}
}}}
{\b0 \cf1 \f2 \i0 \fs16 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
N.D.Ill., 
}
}
{\b0 \cf1 \f2 \i0 \fs16 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
December 1, 2020
\par {\pntext }
}
}
}
}
}
}
}
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
905 F.3d 1363
\par 
}
}
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li0 
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
United States Court of Appeals, Federal Circuit.
\par 
}
}
}
{\b0 \qc \cf20 \f3 \ri120 \i0 \fs24 \li120 
{\b0 \qc \cf20 \f3 \ri120 \i0 \fs24 \li120 
{\b0 \qc \cf20 \f3 \ri120 \i0 \fs24 \li120 
{\b0 \cf20 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb240 
ROCHE MOLECULAR SYSTEMS, INC., Plaintiff-Appellant
\par 
}
}
{\b0 \qc \cf20 \f3 \ri120 \i0 \fs24 \li120 
{\b0 \cf20 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
v.
\par 
}
}
{\b0 \qc \cf20 \f3 \ri120 \i0 \fs24 \li120 
{\b0 \cf20 \f3 \ul0 \strike0 \i0 \fs24 \sa240 \sb0 
CEPHEID, Defendant-Appellee
\par 
}
}
}
}
{\b0 \qc \cf1 \f2 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
2017-1690
\par 
}
}
}
{\b0 \cf1 \f3 \i0 \fs20 
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
|
\par 
}
}
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa200 \sb0 
Decided: October 9, 2018
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf21 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_synopsis_4}{\*\bkmkend co_synopsis_4}
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
Synopsis
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Background:
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Owner of patent directed to methods for detecting the pathogenic bacterium Mycobacterium tuberculosis (MTB) brought infringement action. Competitor moved for summary judgment on invalidity. The United States District Court for the Northern District of California, No. 3:14-cv-03228-EDL, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0170076401&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Elizabeth D. Laporte
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, United States Magistrate Judge, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2043361339&pubNum=0000999&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
2017 WL 6311568
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, granted motion. Patent owner appealed.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Holdings:
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The Court of Appeals, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0156955701&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Reyna
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
, Circuit Judge, held that:
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
primer claims were directed to patent-ineligible natural phenomenon;
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
method claims were directed to a patent-ineligible natural phenomenon; and
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
method claims did not contain an inventive concept that transformed eleven position-specific signature nucleotides of gene into patent-eligible subject matter.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Affirmed.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0101660301&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
O\u8217\'3fMalley
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Circuit Judge, filed a concurring opinion.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1364_4}{\*\bkmkend co_pp_sp_506_1364_4}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1364
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Appeal from the United States District Court for the Northern District of California in No. 3:14-cv-03228-EDL, Magistrate Judge 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0170076401&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Elizabeth D. Laporte
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
.
\par 
}
}
}
{\b1 \cf21 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_attorneysAndLawFirms_4}{\*\bkmkend co_attorneysAndLawFirms_4}
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
Attorneys and Law Firms
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0107217201&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Stephen S. Rabinowitz
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Hughes Hubbard & Reed LLP, New York, NY, argued for plaintiff-appellant. Also represented by 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0201282901&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
James W. Dabney
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0154204401&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Mitchell Epner
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0308125701&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Patrice Polyxene Jean
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0378257001&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
David E. Lansky
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0356431101&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
LYNN M. RUSSO
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0325760101&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Erik R. Puknys
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, Palo Alto, CA, argued for defendant-appellee. Also represented by 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0263379901&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Michael Paul Barker
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0189324701&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Grant L. Kim
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0225447701&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Wesley Ellsworth Overson
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, Morrison & Foerster LLP, San Francisco, CA.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Before 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0101660301&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
O\u8217\'3fMalley
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0156955701&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Reyna
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0211865201&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Hughes
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, Circuit Judges.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf21 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_opinion_4}{\*\bkmkend co_opinion_4}
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
Opinion
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I00f841f3a4e411eabb3da6547d343}{\*\bkmkend co_anchor_I00f841f3a4e411eabb3da6547d343}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Concurring opinion filed by Circuit Judge 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0101660301&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
O\u8217\'3fMalley
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb600 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0156955701&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Reyna
}}}
\sa200 
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
, Circuit Judge.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I0137bbf2a4e411eabb3da6547d343}{\*\bkmkend co_anchor_I0137bbf2a4e411eabb3da6547d343}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1365_4}{\*\bkmkend co_pp_sp_506_1365_4}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1365
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Appellant Roche Molecular Systems, Inc. (\u8220\'3fRoche\u8221\'3f) owns 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997325521&pubNum=0004074&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=PA&docFamilyGuid=I109efea0745011d7a94bace56a9eba1c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent No. 5,643,723 (\u8220\'3fthe \u8217\'3f723 patent\u8221\'3f)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, titled \u8220\'3fDetection of a Genetic Locus Encoding Resistance to Rifampin in Microbacterial Cultures and in Clinical Specimens.\u8221\'3f The United States District Court for the Northern District of California found that the asserted claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997325521&pubNum=0004074&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=PA&docFamilyGuid=I109efea0745011d7a94bace56a9eba1c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f723 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are directed to patent-ineligible subject matter and are therefore invalid under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Roche appeals from a grant of summary judgment of invalidity. We 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
affirm
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I013969a1a4e411eabb3da6547d343}{\*\bkmkend co_anchor_I013969a1a4e411eabb3da6547d343}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
I. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997325521&pubNum=0004074&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=PA&docFamilyGuid=I109efea0745011d7a94bace56a9eba1c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f723 Patent
}}}
\sa200 
\sb400 
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997325521&pubNum=0004074&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=PA&docFamilyGuid=I109efea0745011d7a94bace56a9eba1c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f723 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is directed to methods for detecting the pathogenic bacterium Mycobacterium 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic2ccfb5e475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
tuberculosis
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fM. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic2ccfb5e475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
tuberculosis
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8221\'3f or \u8220\'3fMTB\u8221\'3f). 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997325521&pubNum=0004074&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=PA&docFamilyGuid=I109efea0745011d7a94bace56a9eba1c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f723 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 2 ll. 50\u8211\'3f54. MTB infection is a major cause of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic2ccfb5e475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
tuberculosis
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. col. 1 ll. 13\u8211\'3f30. In 1994, before the priority date of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997325521&pubNum=0004074&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=PA&docFamilyGuid=I109efea0745011d7a94bace56a9eba1c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f723 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the general method of MTB detection in a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic2ccfb5e475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
tuberculosis
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 patient was known as 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ibc288a99475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
sputum examination
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 by the acid-fast bacilli smear. For this test, a biological sample taken from a patient is subjected to cell culture in a process that can take three to eight weeks. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. col. 2 ll. 9\u8211\'3f11. This test has limitations: it can identify the presence of bacterial cells in a biological sample, but cannot identify the cells as MTB. There is a need to know whether the MTB from a patient is resistant to antibiotics. The standard of care for MTB treatment at the time involved a regimen of antibiotics, with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3ab2c96f475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
rifampin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 being a first-line anti-tuberculosis drug. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 1 ll. 31\u8211\'3f33. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic2ccfb5e475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Tuberculosis
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 outbreaks, however, still resulted because of delays in diagnosis and reporting of rifampin-resistant 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic2ccfb5e475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
tuberculosis
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 due to the inability to rapidly identify MTB strains that are resistant to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3ab2c96f475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
rifampin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and put a patient on an appropriate alternative therapy. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 1 ll. 61\u8211\'3f65.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Prior to the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997325521&pubNum=0004074&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=PA&docFamilyGuid=I109efea0745011d7a94bace56a9eba1c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f723 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, scientists in the field had been working on diagnostic tests for faster detection of MTB, particularly rifampin-resistant MTB strains. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. col. 2 ll. 18\u8211\'3f46. It was speculated that \u8220\'3f[g]enotypic detection of multi-drug resistant MTB [strains] directly from clinical specimens is theoretically the fastest and most direct step toward determining effective therapy for patients.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. col. 2 ll. 39\u8211\'3f42. It was known in the art that 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3ab2c96f475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
rifampin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 has a unique site of action on a particular gene that encodes the \u946\'3f subunit of bacterial RNA polymerase (\u8220\'3fthe 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
rpoB
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 gene\u8221\'3f). 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. col. 1 ll. 31\u8211\'3f42. The 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
rpoB
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 gene is present in MTB and other bacterial species, and its deoxyribonucleic acid (\u8220\'3fDNA\u8221\'3f) sequences were known to be highly conserved, with little variation from one bacterial species to another. In 1994, single site mutations in the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
rpoB
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 gene that confer 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3ab2c96f475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
rifampin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 resistance in some bacteria, such as Escherichia coli (\u8220\'3fE. coli\u8221\'3f), were well characterized, making 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
rpoB
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 a prime candidate for studying 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3ab2c96f475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
rifampin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 resistance in MTB. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. col. 1 ll. 42\u8211\'3f52.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The inventors of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997325521&pubNum=0004074&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=PA&docFamilyGuid=I109efea0745011d7a94bace56a9eba1c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f723 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8212\'3fscientists from Roche and the Mayo Foundation for Medical Education and Research (\u8220\'3fMayo\u8221\'3f)\u8212\'3fsequenced the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
rpoB
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 gene from various bacteria species, including MTB, 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1366_4}{\*\bkmkend co_pp_sp_506_1366_4}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1366
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 obtained from a commercial vendor.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00012045678900_ID0ECZAG_4}{\*\bkmkend co_fnRef_B00012045678900_ID0ECZAG_4}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00012045678900_4" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
1
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. col. 8 ll. 1\u8211\'3f3 and col. 8 l. 15\u8211\'3fcol. 9 l. 20. After comparing 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
rpoB
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 DNA sequences across different species, the inventors discovered that the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
rpoB
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 gene in MTB contains eleven \u8220\'3fposition-specific \u8216\'3fsignature nucleotides\u8217\'3f \u8221\'3f (i.e., naturally occurring single nucleotide mutations) that are only present in MTB but not in other bacteria. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. col. 2 l. 60\u8211\'3fcol. 3 l. 2. In other words, these naturally occurring signature nucleotides are like finger-prints of MTB: if an investigator detects one of the eleven signature nucleotides from a biological sample, she knows the sample contains MTB, and vice versa. These signature nucleotides, therefore, could be used to identify MTB using genetic testing, which is both faster and more accurate than the traditional MTB detection methods. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. col. 2 ll. 9\u8211\'3f31.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Based on these eleven MTB-specific signature nucleotides, the Roche inventors devised a diagnostic test that could (1) identify whether or not a biological sample contains MTB, and (2) if MTB is present, predict whether that MTB is a strain that is resistant to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3ab2c96f475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
rifampin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 treatment. The diagnostic test of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997325521&pubNum=0004074&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=PA&docFamilyGuid=I109efea0745011d7a94bace56a9eba1c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f723 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 involves subjecting DNA extracted from a biological sample taken from a patient (e.g., a tissue or fluid sample) to amplification by 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ic0f729ad475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
polymerase chain reaction
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fPCR\u8221\'3f) using a short, single-stranded nucleotide sequence (a \u8220\'3fprimer\u8221\'3f) that can hybridize (i.e., bind) to at least one of the eleven position-specific signature nucleotides in the MTB 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
rpoB
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 gene.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
PCR is a method of amplifying DNA exponentially. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2043361339&pubNum=0000999&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Roche
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 2017 WL 6311568, at *2
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. In PCR, a pair of primers effectively \u8220\'3fflanks,\u8221\'3f or marks the start and finish of, the DNA segment\u8212\'3fe.g., the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
rpoB
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 gene or a portion of it\u8212\'3fto be copied. Strands of DNA are then replicated between the primer pair by a DNA polymerase. This process is repeated until a sufficient number of copies of the desired DNA segment are generated. These copies, known as \u8220\'3famplification product,\u8221\'3f make it possible to detect whether a specific type of DNA is present. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2043361339&pubNum=0000999&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 It is undisputed that by the time of the invention in 1994, PCR had become a well-understood, routine, and conventional technique. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2043361339&pubNum=0000999&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
}}}
\par 
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
After PCR is performed, the presence of DNA amplification product in sufficient copies from the reaction indicates that MTB is present in the biological sample. The absence of DNA amplification product (i.e., below the detection limit using standard assays) indicates that MTB is absent from the biological sample. The amplified 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
rpoB
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 DNA segment from the PCR can, in turn, be tested for the presence of known genetic mutations associated with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3ab2c96f475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
rifampin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 resistance. Thus, the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997325521&pubNum=0004074&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=PA&docFamilyGuid=I109efea0745011d7a94bace56a9eba1c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f723 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 represents an improvement over the traditional 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ibc288a99475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
sputum examination
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 method for detecting MTB, as its genetics-based diagnostic method is faster and more accurate.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997325521&pubNum=0004074&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=PA&docFamilyGuid=I109efea0745011d7a94bace56a9eba1c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f723 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 provides two types of claims: (1) composition-of-matter claims for the primers used in the PCR, which could hybridize to the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
rpoB
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 gene of MTB at a site that includes at least one of the eleven signature nucleotides (\u8220\'3fthe primer claims\u8221\'3f); and (2) process claims for methods for detecting MTB that include amplifying target sequences by PCR and detecting amplification products, which, if present, indicate the presence of MTB (\u8220\'3fthe method claims\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Claims 1\u8211\'3f13 are the method claims. Claim 1, the sole independent method claim, recites:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
1. A method for detecting Mycobacterium 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic2ccfb5e475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
tuberculosis
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 in a biological sample 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1367_4}{\*\bkmkend co_pp_sp_506_1367_4}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1367
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 suspected of containing M. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic2ccfb5e475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
tuberculosis
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 comprising:
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(a) subjecting DNA from the biological sample to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ic0f729ad475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
polymerase chain reaction
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 [PCR] using a plurality of primers under reaction conditions sufficient to simplify a portion of a M. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic2ccfb5e475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
tuberculosis
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 rpoB [gene] to produce an amplification product, wherein the plurality of primers comprises at least one primer that hybridizes under hybridizing conditions to the amplified portion of the [gene] at a site comprising at least one position-specific M. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic2ccfb5e475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
tuberculosis
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 signature nucleotide selected, with reference to FIG. 3 (SEQ ID NO: 1), from the group consisting
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li600 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li600 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
a G at nucleotide position 2312,
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li600 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li600 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
a T at nucleotide position 2313,
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li600 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li600 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
an A at nucleotide position 2373,
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li600 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li600 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
a G at nucleotide position 2374,
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li600 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li600 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
an A at nucleotide position 2378,
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li600 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li600 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
a G at nucleotide position 2408,
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li600 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li600 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
a T at nucleotide position 2409,
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li600 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li600 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
an A at nucleotide position 2426,
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li600 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li600 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
a G at nucleotide position 2441,
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li600 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li600 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
an A at nucleotide position 2456, and
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li600 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li600 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
a T at nucleotide position 2465; and
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(b) detecting the presence or absence of an amplification product, wherein the presence of an amplification product is indicative of the presence of M. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic2ccfb5e475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
tuberculosis
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 in the biological sample and wherein the absence of the amplification product is indicative of the absence of M. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic2ccfb5e475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
tuberculosis
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 in the biological sample.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997325521&pubNum=0004074&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=PA&docFamilyGuid=I109efea0745011d7a94bace56a9eba1c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f723 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 25 l. 57\u8211\'3fcol. 27 l. 6.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00022045678900_ID0E2FBG_4}{\*\bkmkend co_fnRef_B00022045678900_ID0E2FBG_4}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00022045678900_4" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
2
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Dependent claims 2\u8211\'3f13 add various limitations to claim 1 concerning 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Iabd5ebb9475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
PCR
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Iabd5ebb9475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
PCR analysis
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and primer preparation details.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Claims 17\u8211\'3f20 are the primer claims. Independent claim 17 is representative and recites:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
17. A primer having 14\u8211\'3f50 nucleotides that hybridizes under hybridizing conditions to an M. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic2ccfb5e475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
tuberculosis
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 rpoB [gene] at a site comprising at least one position-specific M. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic2ccfb5e475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
tuberculosis
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 signature nucleotide selected, with reference to FIG. 3 (SEQ ID NO: 1), from the group consisting of [the same 11 nucleotides at the positions disclosed in claim 1].
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. col. 28 ll. 14\u8211\'3f31. Dependent claims 18\u8211\'3f20 each add further limitations.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00032045678900_ID0E6IBG_4}{\*\bkmkend co_fnRef_B00032045678900_ID0E6IBG_4}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00032045678900_4" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
3
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 28 ll. 32\u8211\'3f46. Dependent claim 20, for example, discloses full DNA sequences of certain primers. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. col. 28 ll. 44\u8211\'3f46.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I015025f1a4e411eabb3da6547d343}{\*\bkmkend co_anchor_I015025f1a4e411eabb3da6547d343}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
II. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
District Court Proceeding
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Appellee Cepheid makes and sells \u8220\'3fXpert\u174\'3f MTB/RIF Assay,\u8221\'3f an assay that can detect MTB in a biological sample and can identify rifampin-resistant MTB. Roche brought a patent infringement case against Cepheid asserting that Cepheid\u8217\'3fs product infringed the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997325521&pubNum=0004074&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=PA&docFamilyGuid=I109efea0745011d7a94bace56a9eba1c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f723 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2043361339&pubNum=0000999&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Roche
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 2017 WL 6311568, at *1
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Cepheid filed a motion for summary judgment, arguing that all of the asserted claims claim patent-ineligible subject matter under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2043361339&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. at *9
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The district court granted Cepheid\u8217\'3fs motion. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2043361339&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. at *19
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The district court found that the primer claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997325521&pubNum=0004074&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=PA&docFamilyGuid=I109efea0745011d7a94bace56a9eba1c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f723 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, \u8220\'3fwhich have genetic sequences identical to those found in nature, are indistinguishable from those held to be directed to nonpatentable subject matter\u8221\'3f and are thus invalid. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2043361339&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. at *14
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The district court also found that the method claims are invalid 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1368_4}{\*\bkmkend co_pp_sp_506_1368_4}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1368
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 because they are directed to \u8220\'3fnonpatentable laws of nature or natural phenomena\u8221\'3f and \u8220\'3fthe use of newly developed, nonpatentable primers to bind to newly identified naturally occurring signature nucleotides ... using the well-known, routine process of PCR in a conventional way does not transform the claimed methods into\u8221\'3f patent-eligible subject matter. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2043361339&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. at *16\u8211\'3f17
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Roche timely appealed. We have jurisdiction under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=28USCAS1295&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_7b9b000044381" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
28 U.S.C. \u167\'3f 1295(a)(1)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I015221c1a4e411eabb3da6547d343}{\*\bkmkend co_anchor_I015221c1a4e411eabb3da6547d343}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
III. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
Discussion
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B12045678900_4}{\*\bkmkend co_anchor_B12045678900_4}
}
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B22045678900_4}{\*\bkmkend co_anchor_B22045678900_4}
}
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B32045678900_4}{\*\bkmkend co_anchor_B32045678900_4}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
We review the grant of summary judgment under the law of the regional circuit, in this case the Ninth Circuit. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2031166747&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_1378&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1378" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Charles Mach. Works, Inc. v. Vermeer Mfg. Co.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 723 F.3d 1376, 1378 (Fed. Cir. 2013)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The Ninth Circuit reviews the grant or denial of summary judgment de novo. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2004180225&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_1017&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1017" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Leever v. Carson City
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 360 F.3d 1014, 1017 (9th Cir. 2004)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. We also review de novo the question of whether a claim is invalid under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2044364596&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_1384&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1384" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Voter Verified, Inc. v. Election Sys. & Software LLC
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 887 F.3d 1376, 1384 (Fed. Cir. 2018)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B42045678900_4}{\*\bkmkend co_anchor_B42045678900_4}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The only issues on appeal are whether the aforementioned primer claims and the method claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997325521&pubNum=0004074&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=PA&docFamilyGuid=I109efea0745011d7a94bace56a9eba1c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f723 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are patent-ineligible within the meaning of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Section
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 provides that \u8220\'3f[w]hoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. There are certain exceptions to this provision: laws of nature, natural phenomena, and abstract ideas are not patent-eligible subject matter. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_708_2354&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2354" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice Corp. v. CLS Bank Int\u8217\'3fl
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 573 U.S. 208, 134 S.Ct. 2347, 2354, 189 L.Ed.2d 296 (2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (collecting cases).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B52045678900_4}{\*\bkmkend co_anchor_B52045678900_4}
}
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B62045678900_4}{\*\bkmkend co_anchor_B62045678900_4}
}
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B72045678900_4}{\*\bkmkend co_anchor_B72045678900_4}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Supreme Court has established a two-step framework for distinguishing patents that claim laws of nature, natural phenomena, and abstract ideas from those that claim patent-eligible applications of those concepts. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_708_2355&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2355" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 2355
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_780_77&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_77" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo Collaborative Servs. v. Prometheus Labs., Inc.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. 66, 77\u8211\'3f79, 132 S.Ct. 1289, 182 L.Ed.2d 321 (2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ). Under the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}}}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
/
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 two-step framework, we first \u8220\'3fdetermine whether the claims at issue are 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
directed to
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 one of those patent-ineligible concepts.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (emphasis added); 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038839002&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_1335&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1335" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Enfish, LLC v. Microsoft Corp.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 822 F.3d 1327, 1335 (Fed. Cir. 2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. \u8220\'3f[T]he \u8216\'3fdirected to\u8217\'3f inquiry applies a stage-one filter to claims, considered in light of the specification, based on whether \u8216\'3ftheir character as a whole is directed to excluded subject matter.\u8217\'3f \u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038839002&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_1335&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1335" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Enfish
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 822 F.3d at 1335
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036525254&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_1346&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1346" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Internet Patents Corp. v. Active Network, Inc.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 790 F.3d 1343, 1346 (Fed. Cir. 2015)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ). At step one, \u8220\'3fit is not enough to merely identify a patent-ineligible concept underlying the claim; we must determine whether that patent-ineligible concept is what the claim is \u8216\'3fdirected to.\u8217\'3f \u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_1050&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1050" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Rapid Litig. Mgmt. Ltd. v. CellzDirect, Inc.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 827 F.3d 1042, 1050 (Fed. Cir. 2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B82045678900_4}{\*\bkmkend co_anchor_B82045678900_4}
}
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B92045678900_4}{\*\bkmkend co_anchor_B92045678900_4}
}
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B102045678900_4}{\*\bkmkend co_anchor_B102045678900_4}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
If a claim is directed to one of those patent-ineligible concepts, we move to step two of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}}}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
/
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 inquiry to \u8220\'3fexamine the elements of the claim to determine whether it contains an \u8216\'3finventive concept\u8217\'3f sufficient to \u8216\'3ftransform\u8217\'3f the claimed abstract idea into a patent-eligible application.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_708_2357&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2357" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 134 S.Ct. at 2357
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_780_72&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_72" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. at 72\u8211\'3f73, 78, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). At step two, there must be a further inventive concept to take the claim into the realm of patent-eligibility. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 For claims that encompass natural phenomena, the method steps are the \u8220\'3fadditional features that must be new and useful.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036438466&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_1377&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1377" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ariosa Diagnostics, Inc. v. Sequenom, Inc.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 788 F.3d 1371, 1377 (Fed. Cir. 2015)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038639328&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_1376&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1376" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Genetic Techs. Ltd. v. Merial L.L.C.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 818 F.3d 1369, 1376 (Fed. Cir. 2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
cert. denied
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1369_4}{\*\bkmkend co_pp_sp_506_1369_4}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1369
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039558658&pubNum=0000708&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8211\'3f\u8211\'3f\u8211\'3f U.S. \u8211\'3f\u8211\'3f\u8211\'3f\u8211\'3f, 137 S.Ct. 242, 196 L.Ed.2d 135 (2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Following the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}}}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
/
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 framework, we address the primer claims and the method claims in turn.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I0159e9f1a4e411eabb3da6547d343}{\*\bkmkend co_anchor_I0159e9f1a4e411eabb3da6547d343}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
A. The Primer Claims
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B112045678900_4}{\*\bkmkend co_anchor_B112045678900_4}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Roche argues that at 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}}}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
/
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 step one, the primer claims (claims 17\u8211\'3f20) are patent-eligible because they are directed to artificial, man-made primers that are different from naturally occurring DNA. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2043361339&pubNum=0000999&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Roche
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 2017 WL 6311568, at *10
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Specifically, Roche argues that the claimed primers have both a 3-prime end and a 3-prime hydroxyl group, while the naturally occurring bacterial MTB DNA contains neither of these. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2043361339&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. at *11
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The district court rejected Roche\u8217\'3fs arguments and found that \u8220\'3fthe primer claims in this case, which have genetic sequences identical to those found in nature, are indistinguishable from those held to be directed to nonpatentable subject matter in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
In Re BRCA1
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2043361339&pubNum=0000999&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. at *14
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_760&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_760" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
In re BRCA1- & BRCA2-Based Hereditary Cancer Test Patent Litig.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 774 F.3d 755, 760 (Fed. Cir. 2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8221\'3f) ). We agree.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 forecloses Roche\u8217\'3fs arguments. There, this court examined the subject matter eligibility of similar primer claims and held that those primers \u8220\'3fare not distinguishable from the isolated DNA found patent-ineligible in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000708&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8221\'3f and thus are not patent-eligible. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_760&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_760" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 774 F.3d at 760
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000780&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_780_591&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_591" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ass\u8217\'3fn for Molecular Pathology v. Myriad Genetics, Inc.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 569 U.S. 576, 591, 133 S.Ct. 2107, 186 L.Ed.2d 124 (2013)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ). It is well established that primers are short, single-stranded nucleic acid molecules that bind to their complementary nucleotide sequence.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00042045678900_ID0EHGAI_4}{\*\bkmkend co_fnRef_B00042045678900_ID0EHGAI_4}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00042045678900_4" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
4
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_761&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_761" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. at 761
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2043361339&pubNum=0000999&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Roche
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 2017 WL 6311568, at *10
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. As this court found in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, \u8220\'3f[p]rimers necessarily contain the identical sequence of the [nucleotide] sequence directly opposite to the [DNA] strand to which they are designed to bind. They are structurally identical to the ends of DNA strands found in nature.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_760&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_760" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
774 F.3d at 760
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The court further held:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
A DNA structure with a function similar to that found in nature can only be patent eligible as a composition of matter if it has a unique structure, different from anything found in nature. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000708&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_708_2116&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2116" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 133 S.Ct. at 2116\u8211\'3f17
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
. Primers do not have such a different structure and are patent ineligible.
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_761&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_761" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. at 761
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citation omitted).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
It is undisputed that the primers before us have the identical nucleotide sequences as naturally occurring DNA, just like the primers found subject matter ineligible in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Appellant Br. 23 (admitting that \u8220\'3fthe claimed primers include DNAs with the same nucleotide sequence as portions of the MTB 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
rpoB
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 gene\u8221\'3f). Nothing in the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997325521&pubNum=0004074&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=PA&docFamilyGuid=I109efea0745011d7a94bace56a9eba1c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f723 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 suggests that the Roche inventors introduced any mutations that would have made the primers\u8217\'3f nucleotide sequences different from those found in nature. Thus, Roche\u8217\'3fs primers are indistinguishable from their corresponding nucleotide sequences on the naturally occurring MTB 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
rpoB
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 gene.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Roche argues that the claimed primers are nonetheless patent-eligible because they \u8220\'3fare chemically and structurally distinct from any nucleic acid that occurs in nature or that can be isolated from naturally occurring DNA.\u8221\'3f Appellant Br. 23. According to Roche, its claimed primers have a 3-prime end and a 3-prime hydroxyl group, which are absent in naturally occurring DNA. This distinction is unavailing. The same argument was raised in the opening brief in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1370_4}{\*\bkmkend co_pp_sp_506_1370_4}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1370
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2043361339&pubNum=0000999&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Roche
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 2017 WL 6311568, at *14
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citing Appellant Br. at 11\u8211\'3f12, 65\u8211\'3f66, 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 774 F.3d 775 (Nos. 14\u8211\'3f1361, \u8211\'3f1366), 2014 WL 1668324). This court rejected this argument, holding that the primers at issue were patent-ineligible subject matter. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_761&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_761" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 774 F.3d at 761
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. As we held in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, \u8220\'3fit makes no difference that the identified gene sequences are synthetically replicated.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_760&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_760" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. at 760
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. It was undisputed that the primers in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 contain 3-prime ends and 3-prime hydroxyl groups, exactly as Roche\u8217\'3fs primers in this case. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2043361339&pubNum=0000999&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Roche
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 2017 WL 6311568, at *14
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Thus, except for the nucleotide sequences, the primers before us are not chemically or structurally different from the primers that we held patent-ineligible in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Roche also contends that 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is distinguishable because, as a bacterium, MTB has \u8220\'3fa circular chromosome, which has neither a 3-prime end nor a 3-prime hydroxyl [group],\u8221\'3f while \u8220\'3f[t]he primers at issue in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 were derived from human DNA, in which each chromosome occurs as a linear molecule.\u8221\'3f Appellant Br. 23, 31. Roche\u8217\'3fs emphasis on the chromosome is misplaced. The shape of MTB\u8217\'3fs chromosomes is not relevant to the inquiry on the subject matter eligibility of the claimed primers. As this court determined in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the subject matter eligibility inquiry of primer claims hinges on comparing a claimed primer to its corresponding DNA 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
segment
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 on the chromosome\u8212\'3fnot the whole chromosome. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_760&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_760" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
774 F.3d at 760\u8211\'3f61
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (emphasizing the appropriate comparison being between the primers and \u8220\'3fthe relevant 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
portion
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 of the naturally occurring sequence\u8221\'3f (emphasis added) ). Neither the claims nor the written description of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997325521&pubNum=0004074&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=PA&docFamilyGuid=I109efea0745011d7a94bace56a9eba1c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f723 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 contain any reference to the circular nature of MTB chromosomes. Indeed, Roche\u8217\'3fs expert admitted that \u8220\'3fwhether a chromosome is linear or circular makes no difference in designing a primer.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2043361339&pubNum=0000999&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Roche
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 2017 WL 6311568, at *12
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Therefore, at 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}}}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
/
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 step one, we find that the asserted primers are indistinguishable from naturally occurring DNA and that the primer claims are directed to a natural phenomenon.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Roche next argues that its primers can be distinguished from the patent-ineligible primers of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 because they can hybridize to only one of eleven position-specific signature nucleotides on the MTB 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
rpoB
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 gene. Appellant Br. 24. This is an 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}}}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
/
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 step two argument: Roche is arguing that the specificity of its primers to the eleven signature nucleotides would \u8220\'3ftransform\u8221\'3f the claimed naturally occurring phenomenon into patent-eligible subject matter. But Roche\u8217\'3fs emphasis on hybridizing to particular DNA sequences is unavailing. A primer that is otherwise patent-ineligible does not gain subject matter eligibility simply because it can selectively hybridize to a certain position of naturally occurring DNA, because a primer having an identical nucleotide sequence to naturally occurring DNA without further chemical modification is a natural phenomenon. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_760&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_760" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 774 F.3d at 760
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Here, the primers before us have no further chemical modification.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00052045678900_ID0ELXAI_4}{\*\bkmkend co_fnRef_B00052045678900_ID0ELXAI_4}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00052045678900_4" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
5
}}}
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The eleven position-specific signature nucleotides on the MTB 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
rpoB
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 gene that Roche\u8217\'3fs primers are designed to hybridize to are naturally occurring; the Roche inventors identified these eleven positions after sequencing MTB DNA. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997325521&pubNum=0004074&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=PA&docFamilyGuid=I109efea0745011d7a94bace56a9eba1c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f723 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 12 ll. 1\u8211\'3f23. In other words, Roche identified these pre-existing position-specific 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1371_4}{\*\bkmkend co_pp_sp_506_1371_4}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1371
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 signature nucleotides; it did not create them. There is no doubt that Roche\u8217\'3fs discovery of these signature nucleotides on the MTB 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
rpoB
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 gene and the designing of corresponding primers are valuable contributions to science and medicine, allowing for faster detection of MTB in a biological sample and testing for rifampin resistance. However, \u8220\'3f[g]roundbreaking, innovative, or even brilliant discovery does not by itself satisfy the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 inquiry.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000780&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_780_591&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_591" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 569 U.S. at 591, 133 S.Ct. 2107
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036438466&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_1379&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1379" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ariosa
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 788 F.3d at 1379
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The primers are not patent-eligible because they can be found in nature, not because they are not valuable scientific discoveries.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
We hold that the primers before us are indistinguishable from their corresponding nucleotide sequences on the naturally occurring DNA, and that the primer claims, therefore, are patent-ineligible within the meaning of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. We next address the asserted method claims.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I01673061a4e411eabb3da6547d343}{\*\bkmkend co_anchor_I01673061a4e411eabb3da6547d343}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
B. The Method Claims
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
At 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}}}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
/
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 step one, the plain language of the asserted method claims, viewed in light of the written description, demonstrates that they are directed to naturally occurring phenomena. The method claims disclose a diagnostic test based on the observation that the presence of the eleven position-specific signature nucleotides of the naturally occurring MTB 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
rpoB
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 gene indicates the presence of MTB in a biological sample. Claim 1, the sole independent method claim, provides \u8220\'3f[a] method for detecting Mycobacterium 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic2ccfb5e475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
tuberculosis
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 in a biological sample\u8221\'3f and contains two steps: (1) PCR amplification of DNA (\u8220\'3fthe amplification step\u8221\'3f), and (2) determination of the presence of MTB based on the presence or absence of PCR amplification product (\u8220\'3fthe detecting step\u8221\'3f). 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997325521&pubNum=0004074&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=PA&docFamilyGuid=I109efea0745011d7a94bace56a9eba1c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f723 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 25 l. 57\u8211\'3fcol. 27 l. 6. The amplification step subjects DNA from a biological sample\u8212\'3fnaturally occurring matter\u8212\'3fto amplification by PCR using primers that are designed to hybridize to at least one of the eleven naturally occurring position-specific signature nucleotides on the MTB 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
rpoB
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 gene. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at col. 25 l. 60\u8211\'3fcol. 26 l. 67. The primers, as discussed above, are indistinguishable from their corresponding naturally occurring segments on DNA. The detecting step of claim 1 is a mental determination step: if a PCR amplification product is detected, MTB is present in the biological sample, and vice versa. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. at col. 27 ll. 1\u8211\'3f6.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Claim 1 establishes that the method claims are 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
directed to
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 a relationship between the eleven naturally occurring position-specific signature nucleotides and the presence of MTB in a sample. In other words, the method claims assert that if an investigator detects a signature nucleotide from a sample, she knows the sample contains MTB. This relationship between the signature nucleotides and MTB is a phenomenon that exists in nature apart from any human action, meaning the method claims are directed to a natural phenomenon, which itself is ineligible for patenting.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B122045678900_4}{\*\bkmkend co_anchor_B122045678900_4}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The written description supports the conclusion that the method claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997325521&pubNum=0004074&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=PA&docFamilyGuid=I109efea0745011d7a94bace56a9eba1c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f723 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are directed to a patent-ineligible natural phenomenon. In the Summary of the Invention, the patent states:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
This invention involves a comparative analysis of the rpoB sequences in MTB, other mycobacteria and related ... bacteria ..
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. demonstrating the heretofore 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
undiscovered presence
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 of a set of MTB-specific position-specific \u8220\'3fsignature nucleotides\u8221\'3f that permits unequivocal identification of MTB ....
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997325521&pubNum=0004074&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=PA&docFamilyGuid=I109efea0745011d7a94bace56a9eba1c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f723 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 2 ll. 60\u8211\'3f65 (emphasis added). The language makes clear what the inventors\u8217\'3f discovery entails: the revelation of a previously undiscovered natural phenomenon. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The patent further states that \u8220\'3f[i]t was found upon inspection of the 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1372_4}{\*\bkmkend co_pp_sp_506_1372_4}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1372
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 sequence alignment that there were eleven sites ... at which the nucleotide observed for Mycobacterium 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic2ccfb5e475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
tuberculosis
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (MTB) differed from all or most related organisms.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 12 ll. 18\u8211\'3f23. Because these signature nucleotides are naturally occurring, we conclude that the method claims, as informed by the written description, are directed to a patent-ineligible natural phenomenon. We turn to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}}}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
/
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
step two.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B132045678900_4}{\*\bkmkend co_anchor_B132045678900_4}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
We hold that the method claims do not contain an inventive concept that transforms the eleven position-specific signature nucleotides of the MTB 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
rpoB
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 gene into patent-eligible subject matter. PCR amplification of DNA is the main action step of the method claims. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997325521&pubNum=0004074&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=PA&docFamilyGuid=I109efea0745011d7a94bace56a9eba1c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f723 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 25 l. 60\u8211\'3fcol. 26 l. 67. The district court found, and Roche does not challenge, that \u8220\'3fthe background techniques of PCR amplification and detection were \u8216\'3f
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
routine
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f when the patent application was filed in 1994.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2043361339&pubNum=0000999&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Roche
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 2017 WL 6311568, at *16
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (emphasis added); Appellant Br. 45 (\u8220\'3fIn the case at bar, the technique of PCR was well known in the prior art.\u8221\'3f). Indeed, the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997325521&pubNum=0004074&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=PA&docFamilyGuid=I109efea0745011d7a94bace56a9eba1c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f723 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 itself makes clear that \u8220\'3f[t]he methods of the present invention use 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
standard PCR techniques
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997325521&pubNum=0004074&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=PA&docFamilyGuid=I109efea0745011d7a94bace56a9eba1c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f723 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 3 ll. 65\u8211\'3f66 (emphasis added). Neither the claims nor the written description of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997325521&pubNum=0004074&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=PA&docFamilyGuid=I109efea0745011d7a94bace56a9eba1c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f723 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 disclose any \u8220\'3fnew and useful\u8221\'3f improvement to PCR protocols or 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Iaea4c377475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
DNA amplification techniques
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 in general. The detecting step of claim 1 is similarly devoid of an inventive concept because it involves a simple mental determination of the presence of MTB based on the presence or absence of a PCR amplification product.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Roche asserts that the method claims constitute more than a patent-ineligible natural phenomenon. Roche argues that at the time of the invention, it was \u8220\'3fnot routine or conventional to use PCR (or any other genetic test) to detect the presence of MTB in a biological sample\u8221\'3f and \u8220\'3funprecedented to perform PCR using the type of primer specified in claims 1 through 13.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2043361339&pubNum=0000999&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Roche
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 2017 WL 6311568, at *15
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; Appellant Br. 42.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B142045678900_4}{\*\bkmkend co_anchor_B142045678900_4}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
While it may be true that Roche inventors were the first to use PCR to detect MTB in a biological sample, being the first to discover a previously unknown naturally occurring phenomenon or a law of nature alone is not enough to confer patent eligibility. Many groundbreaking, innovative, and brilliant discoveries have been held patent-ineligible. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See e.g., 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_780_73&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_73" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. at 73\u8211\'3f77, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (discovery of natural correlation between level of certain metabolites and drug dosage, resulting in claimed method of optimizing treatment using standard techniques to administer the drug and then check if the metabolite level indicated the need for a dosage change); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038639328&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_1374&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1374" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Genetic Techs.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 818 F.3d at 1374
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (discovery of natural correlation between non-coding regions of DNA and the presence of an allele in the coding region, resulting in claimed method of detecting alleles using standard PCR to amplify and detect); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036438466&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_1373&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1373" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ariosa
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 788 F.3d at 1373
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (discovery of natural phenomenon that pregnant women\u8217\'3fs blood contains cffDNA, resulting in claimed methods using standard techniques to amplify and detect cffDNA in maternal blood).
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The Supreme Court in \u8220\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 made clear that transformation into a patent-eligible application requires more than simply stat[ing] the law of nature while adding the words \u8216\'3fapply it.\u8217\'3f \u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036438466&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_1377&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1377" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ariosa
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 788 F.3d at 1377
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (internal quotation marks omitted) (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_780_72&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_72" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. at 72, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}}}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
/
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 step two\u8217\'3fs requirement of \u8220\'3fadditional features that must be new and useful\u8221\'3f is simply not met in this case because the asserted method claims recite standard PCR methods applied to a naturally occurring phenomenon; there is no additional innovation. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036438466&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
id
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
}}}
\par 
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Roche argues that to use its primers to detect MTB \u8220\'3fis no less an inventive act 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1373_4}{\*\bkmkend co_pp_sp_506_1373_4}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1373
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 than to make a specific artificial drug that is effective to treat an MTB infection.\u8221\'3f Appellant Br. 26 (emphasis omitted). We disagree. It is a well-established law of nature that \u8220\'3fcomplementary nucleotide sequences bind to each other.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_761&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_761" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 774 F.3d at 761
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Roche\u8217\'3fs method claims exploit the same law of nature\u8212\'3fthe primer binds to its complementary nucleotide sequence on the MTB 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
rpoB
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 gene. This court\u8217\'3fs holding in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 applies to this case with equal force: the primers \u8220\'3fdo not perform a significantly new function. Rather, [they are] used to form the first step in a [PCR] chain reaction\u8212\'3fa function that is performed because the primer maintains the exact same nucleotide sequence as the relevant portion of the naturally occurring sequence.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Thus, unlike a method of treating a disease with a new drug, Roche\u8217\'3fs method claims do not involve \u8220\'3fa significantly new function\u8221\'3f for the primers.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00062045678900_ID0EKQBI_4}{\*\bkmkend co_fnRef_B00062045678900_ID0EKQBI_4}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00062045678900_4" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
6
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
}}}
\par 
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
This case is distinguishable from 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
CellzDirect
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, where this court vacated a district court\u8217\'3fs decision that the method claims at issue were ineligible for patenting. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_1052&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1052" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
827 F.3d at 1052
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. This court held that while the claims were based on the discovery of a natural phenomenon (the ability of certain liver cells, or hepatocytes, to survive multiple freeze cycles), they were \u8220\'3fdirected to a new and useful 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
laboratory technique
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 for preserving hepatocytes\u8221\'3f\u8212\'3fnamely, freezing and thawing hepatocytes twice even though the prior art taught away from this process. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_1046&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1046" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. at 1046\u8211\'3f51
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (emphasis added) (distinguishing cases that did not invent a new and useful method based on the discovery of a natural phenomenon). This court held that \u8220\'3f[t]his type of constructive process, carried out by an artisan to achieve \u8216\'3fa new and useful end,\u8217\'3f is precisely the type of claim that is eligible for patenting. ... [The inventors] employed their natural discovery to create 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
a new and improved way of preserving hepatocyte cells
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 for later use.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_1048&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1048" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. at 1048
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (emphasis added) (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_708_2354&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2354" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 134 S.Ct. at 2354
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). Unlike the method claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997325521&pubNum=0004074&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=PA&docFamilyGuid=I109efea0745011d7a94bace56a9eba1c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f723 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the invention in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
CellzDirect
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 went beyond applying a known laboratory technique to a newly discovered natural phenomenon, and instead created an entirely new laboratory technique that \u8220\'3fis not simply an observation or 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
detection
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8221\'3f based on the natural phenomenon. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (emphasis added). In contrast, the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997325521&pubNum=0004074&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=PA&docFamilyGuid=I109efea0745011d7a94bace56a9eba1c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f723 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 claims a method of 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
detection
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 based on a natural phenomenon and employs only conventional, well-known laboratory techniques, which are the opposite of those at issue in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
CellzDirect
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00072045678900_ID0EUXBI_4}{\*\bkmkend co_fnRef_B00072045678900_ID0EUXBI_4}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00072045678900_4" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
7
}}}
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1374_4}{\*\bkmkend co_pp_sp_506_1374_4}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1374
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Roche attempts to distinguish its invention from the patent-ineligible method claims in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. In 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, this court invalidated claims 7 and 8, which were directed to methods of diagnosing genetic 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib0dd2702475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
mutations of the BRCA1 gene
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 in patients, as subject matter ineligible.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00082045678900_ID0EI6BI_4}{\*\bkmkend co_fnRef_B00082045678900_ID0EI6BI_4}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00082045678900_4" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
8
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_763&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_763" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
774 F.3d at 763\u8211\'3f65
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Relevant here, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 distinguished the subject matter ineligible method claims 7 and 8 from the potential subject matter eligibility of a different method claim, claim 21, which was not asserted and was thus not at issue; in dicta, the court pointed out that claim 21
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
claims a method of detecting alterations in which the alterations being detected are expressly identified in the specification by tables 11 and 12. These tables expressly identify ten predisposing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib0dd2702475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
mutations of the BRCA1 gene
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 sequence discovered by the patentees. Thus, the detection in claim 21 is limited to the particular mutations the inventors discovered: detecting ten specific mutations from the wild-type, identified as \u8220\'3f[p]redisposing [m]utations,\u8221\'3f for the specific purpose of identifying increased susceptibility to specific 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Iaf34f5c3475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cancers
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
. Claims 7 and 8 are significantly broader and more abstract, as they claim all comparisons between the patient\u8217\'3fs BRCA genes and the wild-type BRCA genes.
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_765&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_765" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. at 765
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (footnote and citations omitted).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B152045678900_4}{\*\bkmkend co_anchor_B152045678900_4}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Roche argues that its method claims are analogous to claim 21, and distinguishable from claims 7 and 8 in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, because they require primers hybridizing to one of eleven signature nucleotides expressly identified in the claims, and thus would not preempt or limit use of other DNAs for detecting MTB. Appellant Br. 34, 50; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997325521&pubNum=0004074&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=PA&docFamilyGuid=I109efea0745011d7a94bace56a9eba1c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f723 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 26 ll. 58\u8211\'3f68. To be clear, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 did not find claim 21 subject matter eligible; in response to the parties\u8217\'3f arguments, this court emphasized that \u8220\'3fwe express no view\u8221\'3f on whether claim 21 is subject matter eligible, and simply noted that \u8220\'3fclaim 21 is qualitatively different from\u8221\'3f claims 7 and 8. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_765&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_765" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
774 F.3d at 765
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Roche is mistaken that limiting the scope of an otherwise ineligible method claim would necessarily confer subject matter eligibility. Roche\u8217\'3fs attempt to limit the breadth of the method claims by showing alternative uses of MTB DNA outside of the scope of the claims \u8220\'3fdoes not change the conclusion that the claims are directed to patent ineligible subject matter.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036438466&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_1379&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1379" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ariosa
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 788 F.3d at 1379
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. \u8220\'3fWhile preemption may signal patent ineligible subject matter, the absence of complete preemption does not demonstrate patent eligibility.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036438466&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Thus, the method claims before us cannot gain subject matter eligibility solely because they are limited to specific signature nucleotides.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Therefore, we hold that the asserted method claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997325521&pubNum=0004074&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=PA&docFamilyGuid=I109efea0745011d7a94bace56a9eba1c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f723 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are patent-ineligible because they are directed to a natural phenomenon and lack any inventive concept that transforms them into patent-eligible subject matter.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I01860301a4e411eabb3da6547d343}{\*\bkmkend co_anchor_I01860301a4e411eabb3da6547d343}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
IV. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
Conclusion
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
For the foregoing reasons, we affirm the district court\u8217\'3fs summary judgment ruling.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
AFFIRMED
\par 
}
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I01867831a4e411eabb3da6547d343}{\*\bkmkend co_anchor_I01867831a4e411eabb3da6547d343}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1375_4}{\*\bkmkend co_pp_sp_506_1375_4}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1375
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
Costs
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
No costs.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf21 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_concurrance_opinion_4}{\*\bkmkend co_concurrance_opinion_4}
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I01871472a4e411eabb3da6547d343}{\*\bkmkend co_anchor_I01871472a4e411eabb3da6547d343}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0101660301&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
O\u8217\'3fMalley
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, Circuit Judge, concurring.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I01871472a4e411eabb3da6547d343}{\*\bkmkend co_anchor_I01871472a4e411eabb3da6547d343}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
I agree with the majority that our decision in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_758&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_758" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
In re BRCA1- & BRCA2-Based Hereditary Cancer Test Patent Litigation
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 774 F.3d 755, 758 (Fed. Cir. 2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1 
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8221\'3f) compels the conclusion that the primer and method claims of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997325521&pubNum=0004074&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=PA&docFamilyGuid=I109efea0745011d7a94bace56a9eba1c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent No. 5,643,723 (\u8220\'3fthe \u8217\'3f723 patent\u8221\'3f)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are not eligible for patent protection.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
I write separately to express my belief that we should revisit our holding in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at least with respect to the primer claims. Specifically, I believe that our holding there was unduly broad for two reasons: (1) the question raised in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 was narrower than our holding in that case; and, (2) our interpretation of the nature and function of DNA primers lacked the benefit of certain arguments and evidence that the patent owner presents in this case.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
First, the question before us in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 was not whether the primer claims were patent-ineligible, but, rather, whether the district court abused its discretion when it denied the patent owner\u8217\'3fs motion for a preliminary injunction. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_757&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_757" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
774 F.3d at 757
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. After filing an infringement suit in district court, the patent owner in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 moved for a preliminary injunction arguing that it was likely to succeed on the merits of its infringement claim. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032874428&pubNum=0007903&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_7903_1256&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_7903_1256" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
In re BRCA1-, BRCA2-Based Hereditary Cancer Test Patent Litig.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 3 F.Supp.3d 1213, 1256 (D. Utah 2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The district court denied the motion, in part, because it found that the accused infringer had \u8220\'3fraised a substantial question concerning whether [the patent owner]\u8217\'3fs [p]rimer [c]laims are drawn to patent ineligible subject matter.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032874428&pubNum=0007903&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_7903_1263&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_7903_1263" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1263
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The district court made no findings regarding whether the primer claims were indeed patent ineligible. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032874428&pubNum=0007903&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 It correctly acknowledged that, \u8220\'3f[a]t this early stage, ... the court \u8216\'3fdoes not resolve the validity question,\u8217\'3f but instead assesses \u8216\'3fthe persuasiveness of the challenger\u8217\'3fs evidence, recognizing that it is doing so without all the evidence that may come out at trial.\u8217\'3f \u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032874428&pubNum=0007903&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_7903_1257&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_7903_1257" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1257
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2018967540&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_1377&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1377" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Titan Tire Corp. v. Case New Holland, Inc.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 F.3d 1372, 1377 (Fed. Cir. 2009)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The patent owner appealed. We affirmed by expressly concluding that the primer claims were directed to patent-ineligible subject matter. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_757&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_757" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
774 F.3d at 757
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fBecause we hold that these claims are directed to ineligible subject matter under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, we affirm and remand.\u8221\'3f); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_761&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_761" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 761
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fPrimers ... are patent ineligible\u8221\'3f). But that was not the question before us; it was only whether the district court abused its discretion when it found that the accused infringer raised a substantial question regarding invalidity under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Appellants\u8217\'3f Br., 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 2014 WL 1668324, Nos. 14-1361, -1366 (Fed. Cir. Apr. 18, 2014), at *2 (listing in its \u8220\'3fStatement of Issues\u8221\'3f the question of \u8220\'3f[w]hether the district court erred in finding that Ambry raised a substantial question that Myriad\u8217\'3fs pair of primer claims are not directed to patent eligible subject matter ....\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
This procedural context in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is important. We have routinely recognized that the question of whether an accused infringer has raised a substantial question of invalidity in the context of a motion for a preliminary injunction\u8212\'3fsuch as the question before the district court in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8212\'3fpresents a different type of inquiry than the question of whether an asserted claim is invalid\u8212\'3fsuch as the question that was before the district court on summary judgment in this case. Indeed, \u8220\'3f[w]hile the evidentiary burdens at the preliminary injunction stage track the burdens at trial, importantly the ultimate question before the trial court is different\u8221\'3f because \u8220\'3f[i]nstead of the alleged infringer 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1376_4}{\*\bkmkend co_pp_sp_506_1376_4}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1376
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 having to persuade the trial court that the patent is invalid, at [the preliminary injunction] stage[,] it is the patentee, the movant, who must persuade the court that, despite the challenge presented to validity, the patentee nevertheless is likely to succeed at trial on the validity issue.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2018967540&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_1377&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1377" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Titan Tire
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 F.3d at 1377
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Significantly, \u8220\'3fthe trial court \u8216\'3fdoes not resolve the validity question, but rather must ... make an assessment of the persuasiveness of the challenger\u8217\'3fs evidence, recognizing that it is doing so 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
without all of the evidence
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 that may come out at trial.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2018967540&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (emphasis added) (citations omitted).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
This brings me to my second point. Because of the procedural posture in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, it is hardly surprising that we did not have the benefit of certain arguments and evidence that the patent owner presents in this case when we decided 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. As noted, in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, we considered whether claims directed to the following were patent-eligible under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
A pair of single-stranded DNA primers for determination of a nucleotide sequence of a BRCA1 gene by a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ic0f729ad475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
polymerase chain reaction
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the sequence of said primers being derived from human chromosome 17q, wherein the use of said primers in a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ic0f729ad475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
polymerase chain reaction
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 results in the synthesis of DNA having all or part of the sequence of the BRCA1 gene.
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_759&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_759" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
774 F.3d at 759
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1998357609&pubNum=0004074&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=PA&docFamilyGuid=I8da08b90722e11d7a07084608af77b15&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent No. 5,747,282
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 155, ll. 23\u8211\'3f29). In concluding that these claims were not eligible for patent protection, we relied primarily on the Supreme Court\u8217\'3fs decision in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000708&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ass\u8217\'3fn for Molecular Pathology v. Myriad Genetics, Inc.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 569 U.S. 576, 133 S.Ct. 2107, 186 L.Ed.2d 124 (2013)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, which involved other claims related to the BRCA1 gene. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_759&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_759" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 774 F.3d at 759\u8211\'3f61
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000708&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the Supreme Court separately considered the eligibility of claims directed to \u8220\'3fisolated DNA\u8221\'3f having a specific genetic sequence, on the one hand, and those directed to complementary DNA (\u8220\'3fcDNA\u8221\'3f)\u8212\'3fsynthetically created DNA \u8220\'3fwhich contains the same protein-coding information found in a segment of natural DNA but omits portions within the DNA segment that do not code for proteins\u8221\'3f\u8212\'3fon the other. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000780&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_780_580&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_580" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
569 U.S. at 580, 133 S.Ct. 2107
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The Court began its analysis by observing that the patent owner in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000708&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u8220\'3fdid not create or alter any of the genetic information encoded in the BRCA1 and BRCA2 genes,\u8221\'3f nor did it \u8220\'3fcreate or alter the genetic structure of DNA.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000780&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_780_590&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_590" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
569 U.S. at 590, 133 S.Ct. 2107
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. \u8220\'3fInstead, [the patent owner]\u8217\'3fs principal contribution was uncovering the precise location and genetic sequence of the BRCA1 and BRCA2 genes within chromosomes 17 and 13.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000780&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The Court concluded that, in light of this \u8220\'3fprincipal contribution,\u8221\'3f the isolated DNA claims were not eligible for patent protection, while the cDNA claims, which do not occur in nature, were. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000708&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 593\u8211\'3f94, 133 S.Ct. 2107
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Court distinguished the isolated DNA claims from the \u8220\'3fmodified bacterium\u8221\'3f claims held patent-eligible in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1980116775&pubNum=0000708&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Diamond v. Chakrabarty
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 447 U.S. 303, 100 S.Ct. 2204, 65 L.Ed.2d 144 (1980)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000708&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 590\u8211\'3f91, 133 S.Ct. 2107
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. In the Court\u8217\'3fs view, Chakrabarty\u8217\'3fs claims were eligible because his bacterium was \u8220\'3fnew \u8216\'3fwith markedly different characteristics from any found in nature.\u8217\'3f \u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1980116775&pubNum=0000780&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1980116775&pubNum=0000780&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_780_310&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_310" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Chakrabarty
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 447 U.S. at 310, 100 S.Ct. 2204
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). The patent owner in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000708&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, in contrast, \u8220\'3fdid not create anything\u8221\'3f when it isolated DNA having a particular sequence\u8212\'3fthough \u8220\'3fit found an important and useful gene, ... separating that gene from its surrounding genetic material is not an act of invention.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000708&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 591, 133 S.Ct. 2107
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Critically, the Court recognized that claims are not \u8220\'3fsaved by the fact that isolating DNA from the human genome severs chemical bonds and thereby creates a nonnaturally occurring molecule\u8221\'3f: the \u8220\'3fclaims 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1377_4}{\*\bkmkend co_pp_sp_506_1377_4}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1377
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are simply not expressed in terms of chemical composition, nor do they rely in any way on the chemical changes that result from the isolation of a particular section of DNA.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000708&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 593, 133 S.Ct. 2107
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. It went on to explain that \u8220\'3f[i]f the patents depended upon the creation of a unique molecule, then a would-be infringer could arguably avoid at least Myriad\u8217\'3fs patent claims on entire genes ... by isolating a DNA sequence that included both the BRCA1 or BRCA2 gene and one additional nucleotide pair.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000780&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
\par 
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Court reached a different conclusion with respect to the patent owner\u8217\'3fs cDNA claims. The Court began by stating that the \u8220\'3fcreation of a cDNA sequence from mRNA results in an exons-only molecule that is not naturally occurring.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000780&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_780_594&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_594" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 594, 133 S.Ct. 2107
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. It noted that, although viruses can incorporate cDNA into the human genome in rare instances, 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8220\'3f[t]he possibility that an unusual and rare phenomenon might randomly create a molecule similar to one created synthetically through human ingenuity does not render a composition of matter nonpatentable.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000780&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_780_594&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_594" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 594, 133 S.Ct. 2107 n.8
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (emphasis omitted). The Court rejected the accused infringers\u8217\'3f argument that cDNA is not patent eligible because \u8220\'3f[t]he nucleotide sequence of cDNA is dictated by nature, not by the lab technician,\u8221\'3f writing that \u8220\'3fthe lab technician unquestionably creates something new when cDNA is made.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000780&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_780_595&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_595" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 595, 133 S.Ct. 2107
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. This is because, while \u8220\'3fcDNA retains the naturally occurring exons of DNA, ... it is distinct from the DNA from which it was derived\u8221\'3f because the intron sequences are removed. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000780&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Thus, the Court concluded that \u8220\'3fcDNA is not a \u8216\'3fproduct of nature\u8217\'3f and is patent eligible under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, except insofar as very short series of DNA may have no intervening introns to remove when creating cDNA.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000780&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u8220\'3fIn that situation, a short strand of cDNA may be indistinguishable from natural DNA.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000780&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
\par 
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, we discussed 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000708&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3fs teachings, culminating in a summary of that case by citing the Supreme Court\u8217\'3fs observation that, \u8220\'3f[t]o the extent that the exon-only sequence does not exist in nature, the lab technician \u8216\'3funquestionably creates something new when cDNA is made.\u8217\'3f \u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_760&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_760" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
774 F.3d at 760
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000780&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_780_595&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_595" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 569 U.S. at 595, 133 S.Ct. 2107
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). But, in the very next sentence, we concluded that \u8220\'3f[t]he primers before us are not distinguishable from the isolated DNA found patent-ineligible in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000708&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and are not similar to the cDNA found to be patent-eligible.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000780&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 We arrived at this conclusion based on two facts that we perceived as entirely resolving the question of whether primers are structurally identical to that which exists in nature. We found that \u8220\'3f[p]rimers necessarily contain the identical sequence of the BRCA sequence directly opposite to the strand to which they are designed to bind,\u8221\'3f and that \u8220\'3f[t]hey are structurally identical to the ends of DNA strands found in nature.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000780&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
\par 
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
But it is not clear from the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 opinion or record why we reached this conclusion. The lack of record evidence underlying 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1 
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3fs
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 conclusion on this point is important in light of the record in this case. Specifically, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 concludes that primers have \u8220\'3fidentical sequences\u8221\'3f to the natural DNA strands directly opposite the strands to which they bind, but, as the record in this case reveals, a finding that the two have identical 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
sequences
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 does not entirely resolve the question of whether they are 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
structurally
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 identical because structure is not defined solely by nucleotide sequence.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00092045678900_ID0ELNDI_4}{\*\bkmkend co_fnRef_B00092045678900_ID0ELNDI_4}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00092045678900_4" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
1
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Nor is it clear how primers 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1378_4}{\*\bkmkend co_pp_sp_506_1378_4}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1378
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u8220\'3fare structurally identical to the ends of DNA strands found in nature.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000780&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 As I explain below, the additional facts in this record, viewed in the light most favorable to Roche, give rise to genuine issues of material fact
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00102045678900_ID0ENODI_4}{\*\bkmkend co_fnRef_B00102045678900_ID0ENODI_4}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00102045678900_4" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
2
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 regarding whether the claimed primers have a \u8220\'3funique structure, different from anything found in nature,\u8221\'3f and therefore, challenge the conclusion that this entire class of molecules is ineligible under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Roche developed a record in this case demonstrating the ways in which the claimed primers differ structurally from anything that occurs in nature. Roche first submitted evidence supporting a finding that the claimed primers differ from primers that naturally occur in the bacteria of the M. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic2ccfb5e475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
tuberculosis
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 complex (\u8220\'3fMTB\u8221\'3f). Roche\u8217\'3fs expert explained that, unlike the claimed primers, the naturally occurring MTB primers are never single-stranded. 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
J.A. 1892 at \u182\'3f 88. Roche\u8217\'3fs expert also explained that the naturally occurring MTB primers are comprised of RNA whereas the claimed primers are comprised of DNA. J.A. 1892 at \u182\'3f 89. This means that naturally occurring MTB primers differ chemically from the claimed primers \u8220\'3fboth (i) in the type of sugar they contain (
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=Ife6b3add6c7111e18b05fdf15589d8e8&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
ribose
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 [in MTB primers] v. deoxyribose [in the claimed primers] ) and (ii) the sets of bases that they use (A, C, G, U [in the MTB primers] v. A, C, G, T [in the claimed primers] ).\u8221\'3f J.A. 1892 at \u182\'3f 89. Finally, Roche\u8217\'3fs expert explained that \u8220\'3f[n]aturally occurring MTB primers are 3\u8211\'3f10 nucleotides long, and thus differ structurally from the claimed primers, which are at least 14 nucleotides long.\u8221\'3f J.A. 1892 at \u182\'3f 90. This record evidence supports a finding that the claimed primers differ from naturally occurring MTB primers.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Roche also explained that the claimed primers differ structurally from the native MTB 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
rpoB
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 gene. Roche explained that because \u8220\'3fthe DNA of MTB occurs in the form a circular chromosome,\u8221\'3f the native MTB 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
rpoB
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 gene lacks a 3-prime end with a 3-prime hydroxyl (-OH) group. J.A. 1891 at \u182\'3f 85. In contrast, the parties agree that the claimed primers 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
necessarily
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 have hydroxyl groups at their 3-prime end, and that skilled artisans would recognize as much. Roche\u8217\'3fs expert explained that \u8220\'3f[a] free hydroxyl group at the 3\u8217\'3f end of the primer or extension product is 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
essential
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 for DNA replication, because it provides a free end to which the next nucleotide can be attached.\u8221\'3f J.A. 1881 \u182\'3f 40 (emphasis added). Indeed, \u8220\'3f[a] DNA that lacks a free hydroxyl group at the 3\u8217\'3f end cannot support replication and thus cannot serve as a primer.\u8221\'3f J.A. 1881 \u182\'3f 40; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 J.A. 1884\u8211\'3f85 \u182\'3f 48 (\u8220\'3fIf a DNA does not have a free hydroxyl at the 3\u8217\'3f-end, it cannot be a primer.\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Moreover, because the DNA of MTB found in nature occurs in the form of a circular chromosome, and therefore lacks any sort of end, J.A. 1876 at \u182\'3f 26 (\u8220\'3fIf the DNA is in the form of a closed circle, there are no ... 3-prime ends, nor a 3-prime hydroxyl group.\u8221\'3f), the claimed primers cannot be \u8220\'3fstructurally identical to the ends of DNA strands found in nature,\u8221\'3f as we concluded 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_760&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_760" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
in 
}
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 774 F.3d at 760
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. And, even if the DNA in MTB occurred in linear strands, Roche\u8217\'3fs expert testified that, in linear strands of native DNA, only the last nucleotide 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
in the entire strand
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 typically has a hydroxyl group at its 3-prime end. Thus, based on the above evidence, Roche\u8217\'3fs expert concluded that, while a portion of the native MTB 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
rpoB
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 gene has the same nucleotide sequence as 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1379_4}{\*\bkmkend co_pp_sp_506_1379_4}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1379
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the claimed primers, the two differ chemically vis-\u224\'3f-vis the presence of a 3-prime end with a 3-prime hydroxyl group at a nonnaturally occurring location. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 J.A. 1892 at \u182\'3f 86 (\u8220\'3fThus, there is a chemical difference between the primer and the longer DNA strand of which the primer has, in part, the same sequence.\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Said another way, although it is undisputed that all the claimed primers here have nucleotide 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
sequences
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 that are identical to segments of the naturally occurring 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
rpoB
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 gene found in MTB, a genuine factual dispute exists as to whether they have a 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
materially different structure
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 than any DNA molecules typically found in nature. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cf. 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000780&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_780_595&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_595" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 569 U.S. at 595, 133 S.Ct. 2107
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (deeming relevant whether short strands of cDNA are \u8220\'3findistinguishable from natural DNA\u8221\'3f); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1980116775&pubNum=0000780&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_780_310&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_310" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Chakrabarty
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 447 U.S. at 310, 100 S.Ct. 2204
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (holding claims patent-eligible where \u8220\'3fthe patentee has produced a new bacterium with markedly different characteristics from any found in nature and one having the potential for significant utility\u8221\'3f
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Not only does the record demonstrate that the claimed primers could be structurally different from that which exists in nature, but the claims here also appear to be distinguishable from the molecule that would result from isolating the sequence of the strand directly opposite the strand to which the claimed primers hybridize. This is critical because, in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000708&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the Court explained that claims directed to isolated DNA sequences \u8220\'3fare not saved by the fact that isolating DNA from the human genome severs the chemical bonds that bind gene molecules together.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000780&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_780_592&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_592" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
569 U.S. at 592, 133 S.Ct. 2107
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. But, unlike the claims in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000708&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, which were neither \u8220\'3fexpressed in terms of chemical composition, nor\u8221\'3f reliant \u8220\'3fin any way on the chemical changes that result from the isolation of a particular section of DNA,\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000780&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_780_592&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_592" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
569 U.S. at 592, 133 S.Ct. 2107
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the primer claims here, by virtue of being directed to the well-known, structural term \u8220\'3fprimer\u8221\'3f and by virtue of including \u8220\'3f14-50 nucleotides that hybridize[ ] under hybridizing conditions\u8221\'3f to at least one signature nucleotide, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997325521&pubNum=0004074&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=PA&docFamilyGuid=I109efea0745011d7a94bace56a9eba1c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f723 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, col. 28, ll. 14\u8211\'3f31, 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
are
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 expressed in terms of chemical composition and 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
are
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 reliant on the presence of a 3-prime end and a 3-prime hydroxyl group at a nonnaturally occurring location. Therefore, Roche\u8217\'3fs evidence regarding the presence of a 3-prime end with a 3-prime hydroxyl group, coupled with the claim language, support a finding that the claims here are distinguishable from the DNA claims in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000708&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
These structural differences between the claimed primers and that which exists in nature are not my only concerns with our conclusion in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, however: we also held that primers \u8220\'3fdo not perform a significantly new function\u8221\'3f than does naturally occurring DNA. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_761&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_761" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
774 F.3d at 761
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. In reaching this conclusion, we rejected the patentee\u8217\'3fs contention that DNA, when part of the naturally occurring genetic sequence, \u8220\'3fstores the biological information used in the development and functioning of all known living organisms,\u8221\'3f but when isolated as a primer, the DNA fragment \u8220\'3fprime[s], i.e., ... serve[s] as a starting material for a DNA polymerization process.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 We disagreed, writing that:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
[i]n fact, the naturally occurring genetic sequences at issue here 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
do not perform a significantly new function
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Rather, the naturally occurring material is used to form the first step in a chain reaction\u8212\'3fa function that is performed because the primer maintains the exact same nucleotide sequence as the relevant portion of the naturally occurring sequence. One of the primary functions of DNA\u8217\'3fs structure in nature is that complementary nucleotide sequences bind to each other. It is this same function that is exploited here\u8212\'3fthe primer binds to its complementary nucleotide sequence. Thus, just as in nature, primers 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1380_4}{\*\bkmkend co_pp_sp_506_1380_4}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1380
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 utilize the innate ability of DNA to bind to itself.
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_760&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_760" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 760\u8211\'3f61
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (emphasis added). We then concluded that 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000708&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 does not \u8220\'3fconfer[ ] patent eligibility on composition of matter claims directed to naturally occurring DNA strands under such circumstances.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_761&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_761" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 761
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Thus, \u8220\'3f[a] DNA structure with a function similar to that found in nature can only be patent eligible as a composition of matter if it has a unique structure, different from anything found in nature.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citations omitted). We, therefore, held that \u8220\'3f[p]rimers do not have such a different structure and are patent ineligible.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
\par 
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Here, not only is there at least a genuine issue of material fact as to whether the claimed primers have a different 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
structure
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 from anything found in nature, the record also suggests that the claimed primers may have a different 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
function
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 from that of native DNA. Particularly, record evidence shows that, unlike native DNA, which merely stores genetic information and serves as a template for replication, the claimed primers can 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
selectively
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 hybridize, or bind, to specific nucleotides of a target gene\u8212\'3fhere, the \u8220\'3fsignature nucleotides\u8221\'3f of the MTB 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
rpoB
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 gene. This function is reliant on the presence of the free 3-prime hydroxyl group at a nonnaturally occurring location and allows scientists, among other things, to amplify and detect the MTB 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
rpoB
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 gene using techniques such as 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ic0f729ad475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
polymerase chain reaction
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fPCR\u8221\'3f). The fact that claimed primers, once synthesized, \u8220\'3futilize the innate ability of DNA to bind to itself,\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_761&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_761" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 761
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, to achieve this selective hybridization should not render them wholesale patent-ineligible. In 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000708&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the Supreme Court explained that, although \u8220\'3f[t]he nucleotide sequence of cDNA is dictated by nature, not by the lab technician,\u8221\'3f this is irrelevant for 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 purposes because \u8220\'3fthe lab technician unquestionably creates something new when cDNA is made.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000780&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_780_595&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_595" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
569 U.S. at 595, 133 S.Ct. 2107
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Similarly, this record contains evidence that the lab technician creates something new when the claimed primers are made, even though, once made, the primers \u8220\'3futilize the innate ability of DNA to bind to itself.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_760&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_760" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 774 F.3d at 760\u8211\'3f61
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Cepheid argues on appeal that the patent owner in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 pointed to the same differences that Roche points to here. Specifically, Cepheid contends that the patent owner in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 raised the same 3-prime hydroxyl group argument that Roche makes here, and that we squarely rejected that argument. But, that is not an accurate characterization of the record in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. There, the patent owner merely alluded to the structural distinction between primers and native DNA when explaining the functional differences between the two. Appellants\u8217\'3f Br., 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
In re BRCA1
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 2014 WL 1668324, at *50. The only reference the patent owner made to the free 3-prime hydroxyl group was in its statement of facts in its opening brief where it stated that, \u8220\'3f[t]here are no short, single strands of DNA with a free 3\u8217\'3f-OH group in nature that can serve as primers.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at *8. Notably, when attempting to establish the existence of structural differences between native DNA and primers, the patent owner in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000999&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 did not reference the presence of a hydroxyl group at a nonnaturally occurring location and focused instead on the fact that primers are designed and synthetically created in a lab. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at *48\u8211\'3f50. Therefore, perhaps because of the procedural posture in which the issue was developed, the patent owner in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 did not develop a record demonstrating that primers differ structurally from native DNA based on the presence of a hydroxyl group at a nonnaturally occurring location. Nor did we expressly address this hydroxyl group \u8220\'3fargument\u8221\'3f in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000999&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 or include language indicating that we had considered, but rejected, any such argument.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The patent owner in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000999&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 also never argued that its claimed primers were 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1381_4}{\*\bkmkend co_pp_sp_506_1381_4}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1381
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 structurally distinct from naturally occurring primers. While the patent owner in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000999&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 pointed out that \u8220\'3f[t]here are no short, single strands of DNA with a free 3\u8217\'3f-OH group in nature that can serve as primers\u8221\'3f and that \u8220\'3f[i]n natural DNA replication, RNA primers are used as the starting material,\u8221\'3f it never used these facts to demonstrate that the primers at issue were structurally distinct from anything that exists in nature. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000999&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Appellants\u8217\'3f Br., 
}
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 2014 WL 1668324, at *8
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Simply, the patent owner in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033280689&pubNum=0000999&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 did not make the specific arguments Roche makes here.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
These points were also not raised or addressed in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000999&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. While the patent owner there argued that native DNA differs from isolated DNA because \u8220\'3f[n]ative DNA cannot be used as a molecular tool, such as a probe or a primer,\u8221\'3f it did not explain that isolated DNA differs structurally from native DNA vis-\u224\'3f-vis a 3-prime end and a 3-prime hydroxyl group at a nonnaturally occurring location. Myriad\u8217\'3fs Mem. of Law in Support of Mot. for Summary J. and in Opp. to Pl\u8217\'3fs Mot. for Summary J., 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad Genetics v. Assoc. for Molecular Pathology
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, No. 1:09-cv-04515-RWS (S.D.N.Y. Dec. 23, 2009), ECF No. 153, 8\u8211\'3f9. Significantly, and as explained above, the claims at issue in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000999&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 were not reliant on the presence of this 3-prime hydroxyl group at a nonnaturally occurring location. Accordingly, Myriad could not have properly raised, and the Supreme Court could not have considered, the particular points that Roche now raises. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000780&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_780_593&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_593" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 569 U.S. at 593, 133 S.Ct. 2107
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fMyriad\u8217\'3fs claims are simply not expressed in terms of chemical composition, nor do they rely in any way on the chemical changes that result from the isolation of a particular section of DNA.\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Therefore, unlike the appellants in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000708&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000999&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, here, Roche submitted evidence of record that, at the very least, raises genuine issues of material fact as to whether there exists anything in nature that both has the structure and performs the function of the claimed primers. For these reasons, while I agree with the majority that the broad language of our holding in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000999&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 compels the conclusion that the primer claims in this case are ineligible under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, I believe that holding exceeded the confines of the issue raised on appeal and was the result of an underdeveloped record in that case. I believe, accordingly, that we should revisit our conclusion in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000999&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 en banc.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf21 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_allCitations_4}{\*\bkmkend co_allCitations_4}
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
All Citations
\par 
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
905 F.3d 1363, 128 U.S.P.Q.2d 1221
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 \par}\sect\sbknone\pgncont\cols1{\ids0 {
{\trowd \ltrrow \trleft0 
\clpadl200 \clpadfl3 \clbrdrt \clbrdrl \trql \clwWidth10080 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs20 \li0 
{\b0 \cf1 \f4 \i0 \fs20 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Footnotes
\par 
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \ql \li0 \fs20 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00012045678900_4}{\*\bkmkend co_footnote_B00012045678900_4}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00012045678900_ID0ECZAG_4" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
1
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Mayo later assigned its rights in the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997325521&pubNum=0004074&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=PA&docFamilyGuid=I109efea0745011d7a94bace56a9eba1c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u8217\'3f723 patent
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 to Roche. 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2043361339&pubNum=0000999&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Roche Molecular Sys., Inc. v. Cepheid
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, No. 14-CV-03228-EDL, 2017 WL 6311568, at *1 (N.D. Cal. Jan. 17, 2017)
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00022045678900_4}{\*\bkmkend co_footnote_B00022045678900_4}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00022045678900_ID0E2FBG_4" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
2
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Adenine (\u8220\'3fA\u8221\'3f), Thymine (\u8220\'3fT\u8221\'3f), and Guanine (\u8220\'3fG\u8221\'3f), together with Cytosine (\u8220\'3fC\u8221\'3f), constitute the four nucleotide building blocks of DNA. 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2043361339&pubNum=0000999&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Roche
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, 2017 WL 6311568, at *2
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00032045678900_4}{\*\bkmkend co_footnote_B00032045678900_4}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00032045678900_ID0E6IBG_4" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
3
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
The remaining claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997325521&pubNum=0004074&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=PA&docFamilyGuid=I109efea0745011d7a94bace56a9eba1c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u8217\'3f723 patent
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, claims 14\u8211\'3f16 and 21\u8211\'3f23, are also primer claims, but they are not asserted in this litigation.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00042045678900_4}{\*\bkmkend co_footnote_B00042045678900_4}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00042045678900_ID0EHGAI_4" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
4
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Complementarity refers to the inherent property of nucleotides that causes them to pair with each other: Adenine pairs with Thymine, and Cytosine pairs with Guanine. J.A. 1129\u8211\'3f30. This property allows investigators who know the sequence of a single strand of DNA to accurately predict the sequence of the opposite DNA strand. 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Id
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00052045678900_4}{\*\bkmkend co_footnote_B00052045678900_4}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00052045678900_ID0ELXAI_4" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
5
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
We do not address the subject matter eligibility of primers that have been altered\u8212\'3fe.g., investigator-induced mutation(s) such that their nucleotide sequences are not found in nature, or primers which are chemically modified or labeled by investigators such that they cannot be isolated directly from naturally occurring DNA. 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000780&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_780_596&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_596" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Myriad
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, 569 U.S. at 596, 133 S.Ct. 2107
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 (\u8220\'3fScientific alteration of the genetic code presents a different inquiry, and we express no opinion about the application of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u167\'3f
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 
}
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
101
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \chcbpat2 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 to such endeavors.\u8221\'3f).
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00062045678900_4}{\*\bkmkend co_footnote_B00062045678900_4}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00062045678900_ID0EKQBI_4" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
6
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
DNA or RNA can sometimes be used as a drug. For example, technologies such as RNA interference (\u8220\'3fRNAi\u8221\'3f) and small inhibitory RNAs (\u8220\'3fsiRNAs\u8221\'3f) use RNA to silence the expression of individual genes. 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
e.g.
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2031308890&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_1318&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1318" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Univ. of Utah v. Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V.
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, 734 F.3d 1315, 1318 (Fed. Cir. 2013)
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 (an attorneys\u8217\'3f fees case not involving subject matter eligibility of the claims); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038365817&pubNum=0000999&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Ex parte Reich
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, No. 2013-004817, 2016 WL 750325, at *1 (P.T.A.B. Feb. 24, 2016)
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036701051&pubNum=0000999&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Ex parte Khvorova
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, No. 2012-010359, 2015 WL 4267897, at *1 (P.T.A.B. July 10, 2015)
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
. We express no opinion on subject matter eligibility of method claims that exploit DNA or RNA for drug-like new applications.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00072045678900_4}{\*\bkmkend co_footnote_B00072045678900_4}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00072045678900_ID0EUXBI_4" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
7
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Similarly, this case is also distinguishable from 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2044320422&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals International Ltd.
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
,
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 where this court found that the claimed methods of treatment are subject matter eligible because they claim \u8220\'3f \u8216\'3fa new way of using an existing drug\u8217\'3f that is safer for patients\u8221\'3f with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic8ad584c475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
schizophrenia
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 at 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Alice
}
}\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
/
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Mayo
}
}\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 step one. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2044320422&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_1135&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1135" }{\fldrslt 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
887 F.3d 1117, 1135 (Fed. Cir. 2018)
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_780_87&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_87" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Mayo
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, 566 U.S. at 87, 132 S.Ct. 1289
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
). 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
But see 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2044320422&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_1142&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1142" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
id.
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 at 1142
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 (Prost, C.J., dissenting) (stating that the treatment claims are \u8220\'3fno more than an optimization of an existing treatment of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic8ad584c475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
schizophrenia
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, just as the claims in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Mayo
}
}\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u8221\'3f). 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2044320422&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Vanda
}
}\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 \u8220\'3funderscore[s] the distinction between method of treatment claims and those in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Mayo
}
}\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
,\u8221\'3f i.e., claims \u8220\'3fdirected to a diagnostic method.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2044320422&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_1134&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1134" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 at 1134\u8211\'3f
}
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
35
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \chcbpat2 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 (majority opinion). In contrast, Roche\u8217\'3fs method claims, consisting of a standard PCR amplification step and a mental determination step, are not directed to a method of treatment. Every time an investigator practices Roche\u8217\'3fs claimed invention\u8212\'3fdetecting the presence or absence of the eleven signature nucleotides of MTB 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
rpoB
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 gene in a sample\u8212\'3fshe is simply rediscovering a preexisting natural phenomenon. Unlike in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2044320422&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Vanda
}
}\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, Roche does not claim a method of treatment based on an underlying natural phenomenon, but the natural phenomenon itself. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2044320422&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_1135&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1135" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 at 1135
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00082045678900_4}{\*\bkmkend co_footnote_B00082045678900_4}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00082045678900_ID0EI6BI_4" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
8
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Briefly, claim 7 requires \u8220\'3f1) hybridizing a BRCA gene probe and 2) detecting the presence of a hybridization product. Similarly, claim 8 requires 1) amplification of the BRCA1 gene and 2) sequencing of the amplified nucleic acids.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_764&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_764" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
BRCA1
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, 774 F.3d at 764
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00092045678900_4}{\*\bkmkend co_footnote_B00092045678900_4}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00092045678900_ID0ELNDI_4" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
1
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Notably, there can be no dispute that primers, though complementary, are structurally different in sequence from the strands to which they hybridize. Indeed, a primer comprising a nucleotide sequence of ATCG is complementary to, but unquestionably different from, a natural DNA strand comprising a sequence of TAGC.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \lastrow \trleft0 
\clbrdrb \clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrb \clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00102045678900_4}{\*\bkmkend co_footnote_B00102045678900_4}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00102045678900_ID0ENODI_4" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
2
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2044641173&pubNum=0000506&originatingDoc=Ie8967be0cbdc11e88037ff68a1223ab1&refType=RP&fi=co_pp_sp_506_1370&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1370" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Berkheimer v. HP Inc.
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, 890 F.3d 1369, 1370 (Fed. Cir. 2018)
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 (Moore, J., concurring in the denial of rehearing en banc) (\u8220\'3fWhile the ultimate question of patent eligibility is one of law, it is not surprising that it may contain underlying issues of fact.\u8221\'3f).
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }}\par 
}
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 \par}\sect\sbknone\pgncont\cols1{\ids0 {
{\trowd \lastrow \trleft0 
\clpadt24 \clpadft3 \clpadl100 \clpadfl3 \clpadr24 \clpadfr3 \clbrdrt \brdrcf22 \brdrw10 \brdrs \clbrdrb \clbrdrl \trql \clvertalt \clwWidth4320 \cellx4320 
\clpadt29 \clpadft3 \clpadl100 \clpadfl3 \clpadr29 \clpadfr3 \clbrdrt \brdrcf22 \brdrw10 \brdrs \clbrdrb \clbrdrr \trql \clvertalt \clwWidth5760 \cellx10080 
\intbl 
{\ri24 \li24 
{\b1 \cf22 \f4 \ri24 \i0 \ql \fs16 \li24 
{\b1 \cf22 \f4 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
End of Document
\par 
}
}
}\b1 \cf22 \f4 \ri24 \ul0 \strike0 \i0 \ql \li24 \fs16 \sa0 \sb0 \intbl \cell \intbl 
{\ri29 \li29 
{\qr \b0 \cf22 \f4 \ri29 \i0 \fs19 \li29 
{\b0 \cf22 \f4 \ul0 \strike0 \i0 \fs19 \sa0 \sb0 
\u169\'3f 2021 Thomson Reuters. No claim to original U.S. Government Works.
\par 
}
}
}\qr \b0 \cf22 \f4 \ri29 \ul0 \strike0 \i0 \li29 \fs19 \sa0 \sb0 \intbl \cell \row }}\par 
}
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}\sect }